PainReform Ltd
PRFX
Get informed when a big investor buys or sells
+ FollowMarket Cap$241.6K
Close$
$6.42
258.4% upside
Current Fair Value
258.4% upsideUndervalued by 258.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $241,596.00 |
|---|---|
| Enterprise Value | $-2,862,404.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.47 |
| Beta | 0.77 |
| Outstanding Shares | 84,920 |
Return
| Return on Equity | -47.83% |
|---|---|
| Return on Assets | -34.06% |
| Return on Invested Capital | -43.22% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | 0.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.69 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 6, 2026
EPS Estimate
$-672.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.43%▲ 2.43% |
|---|---|
| Total Invested | $31,939 |
| Investors Holding | 4▲ 4.00% |
ESG Score
No data
About PainReform Ltd
2 employeesPainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pai...